eloralintide tirzepatide will be the obesity drug of the future. It will likely be approved to combine with other GLP-1 therapies to achieve greater results. A phase 3 trial for this is already eloralintide vs retatrutide Triple Agonism

The pivotal trials tested 0.25mg as the lowest dose, and even that was considered a non-therapeutic escalation dose

18, 2024 from Durell, N., Franks, R., Coon, S., et al

TRANSCEND-T2D-1 (NCT06354660) will compare the efficacy and safety of retatrutide compared to placebo in people with inadequately controlled T2D treated with diet and exercise over a period of 11 months

These include: Stop taking Rybelsus and seek immediate medical help if you have any of the following serious symptoms: Rybelsus is prescribed to improve blood sugar (glycemic) control for adults with Type 2 diabetes mellitus

The best place for it is the fridge

The structural valve failure that causes varicose veins, spider veins, and chronic venous insufficiency does not reverse with weight loss alone, and GLP-1 medications are not a substitute for vein treatment